Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Biol Sci 2019; 15(12):2548-2560. doi:10.7150/ijbs.34213 This issue Cite

Review

Current Progress in CAR-T Cell Therapy for Solid Tumors

Shuo Ma1,*, Xinchun Li1,*, Xinyue Wang1,*, Liang Cheng1,2, Zhong Li1, Changzheng Zhang1, Zhenlong Ye1,3,4,✉, Qijun Qian1,3,4✉

1. Shanghai Baize Medical Laboratory, Shanghai, China
2. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
3. Shanghai Cell Therapy Research Institute, Shanghai, China
4. Shanghai Engineering Research Center for Cell Therapy, Shanghai, China
* These authors contributed equally to this work.

✉ Corresponding authors: Qijun Qian, Shanghai Baize Medical Laboratory, 75 Qianyang Road, Shanghai 201805, China. Email: qianorg; Zhenlong Ye, Shanghai Baize Medical Laboratory, 75 Qianyang Road, Shanghai 201805, China. Email: yezlorg

Citation:
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci 2019; 15(12):2548-2560. doi:10.7150/ijbs.34213. https://www.ijbs.com/v15p2548.htm
Other styles

File import instruction

Abstract

Graphic abstract

Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US. Despite the progresses made in treating hematological malignancies, challenges still remain for use of CAR-T cell therapy to treat solid tumors. In this landscape, most studies have primarily focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors. To further understand the current status and trend for developing CAR-T cell based therapies for various solid tumors, this review emphasizes on CAR-T techniques, current obstacles, and strategies for application, as well as necessary companion diagnostics for treatment of solid tumors with CAR-T cells.

Keywords: CAR-T cells, chimeric antigen receptor, solid tumors, companion diagnostics, CTC

Citation styles

APA
Ma, S., Li, X., Wang, X., Cheng, L., Li, Z., Zhang, C., Ye, Z., Qian, Q. (2019). Current Progress in CAR-T Cell Therapy for Solid Tumors. International Journal of Biological Sciences, 15(12), 2548-2560. https://doi.org/10.7150/ijbs.34213.

ACS
Ma, S.; Li, X.; Wang, X.; Cheng, L.; Li, Z.; Zhang, C.; Ye, Z.; Qian, Q. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int. J. Biol. Sci. 2019, 15 (12), 2548-2560. DOI: 10.7150/ijbs.34213.

NLM
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci 2019; 15(12):2548-2560. doi:10.7150/ijbs.34213. https://www.ijbs.com/v15p2548.htm

CSE
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. 2019. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci. 15(12):2548-2560.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use